CN113318280B - 一种骨再生超细纤维膜及其制备方法 - Google Patents
一种骨再生超细纤维膜及其制备方法 Download PDFInfo
- Publication number
- CN113318280B CN113318280B CN202110387580.4A CN202110387580A CN113318280B CN 113318280 B CN113318280 B CN 113318280B CN 202110387580 A CN202110387580 A CN 202110387580A CN 113318280 B CN113318280 B CN 113318280B
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- solution
- carbonate powder
- fiber membrane
- precursor solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 52
- 239000000835 fiber Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000010478 bone regeneration Effects 0.000 title claims abstract description 21
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 152
- 239000000243 solution Substances 0.000 claims description 98
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 86
- 239000000843 powder Substances 0.000 claims description 82
- 239000002243 precursor Substances 0.000 claims description 58
- 239000010410 layer Substances 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 238000001035 drying Methods 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 28
- 238000009830 intercalation Methods 0.000 claims description 21
- 230000002687 intercalation Effects 0.000 claims description 21
- 239000012792 core layer Substances 0.000 claims description 19
- 239000011259 mixed solution Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 18
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 17
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 17
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 17
- 108010001441 Phosphopeptides Proteins 0.000 claims description 16
- 229960004343 alendronic acid Drugs 0.000 claims description 16
- 239000005018 casein Substances 0.000 claims description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 16
- 235000021240 caseins Nutrition 0.000 claims description 16
- 229920001610 polycaprolactone Polymers 0.000 claims description 14
- 239000004632 polycaprolactone Substances 0.000 claims description 14
- -1 polyoxyethylene Polymers 0.000 claims description 14
- VFAZUESUCBECNE-UHFFFAOYSA-L calcium;(4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate Chemical compound [Ca+2].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O.NCCCC(O)(P(O)(O)=O)P(O)([O-])=O VFAZUESUCBECNE-UHFFFAOYSA-L 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000006136 alcoholysis reaction Methods 0.000 claims description 10
- 238000010041 electrostatic spinning Methods 0.000 claims description 10
- 238000000227 grinding Methods 0.000 claims description 10
- 238000009987 spinning Methods 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 229920001410 Microfiber Polymers 0.000 claims description 3
- 238000001523 electrospinning Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 16
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 239000012567 medical material Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 210000000963 osteoblast Anatomy 0.000 description 10
- 230000007547 defect Effects 0.000 description 8
- 230000001376 precipitating effect Effects 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 3
- 210000001608 connective tissue cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 238000007664 blowing Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/028—Other inorganic materials not covered by A61L31/022 - A61L31/026
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/02—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from cellulose, cellulose derivatives, or proteins
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/10—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one other macromolecular compound obtained by reactions only involving carbon-to-carbon unsaturated bonds as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/14—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one polyester as constituent
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F8/00—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof
- D01F8/04—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers
- D01F8/16—Conjugated, i.e. bi- or multicomponent, artificial filaments or the like; Manufacture thereof from synthetic polymers with at least one other macromolecular compound obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds as constituent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医用材料技术领域,公开了一种骨再生超细纤维膜及其制备方法,包括将贝壳粉碎研磨,在氧气氛围下经高温焙烧去除有机质,用烷基多糖苷进行插层得有机碳酸钙粉末,再吸附阿仑膦酸钠,之后与酪蛋白磷酸肽一同包载于聚氧化乙烯和聚乙烯醇‑聚己内酯/聚乙烯基吡咯烷酮的核壳超细纤维膜。本发明制备的骨再生超细纤维膜具有促进骨组织再生功能。
Description
技术领域
本发明属于医用材料技术领域,具体涉及一种骨再生超细纤维膜及其制备方法。
背景技术
牙周病、根尖病变、肿瘤、外伤等原因而导致的骨组织缺损是口腔临床治疗中十分棘手的难题。骨缺损修复的目的是为了尽可能地促进受损区的骨组织再生,恢复受损区骨组织的生理形态、结构和基本功能。目前骨缺损修复的方法主要包括骨移植、牵张成骨、骨组织工程、引导骨组织再生术等。
引导骨组织再生术是近年来修复骨缺损的一个新的研究热点,它是根据各类组织细胞迁移速度不同的特点,如上皮细胞和成纤维细胞迁移速度较快,而成骨细胞移行速度较慢,创造出骨组织优势生长的环境,即将屏障膜材料置于软组织与骨缺损之间建立生物屏障,阻止干扰骨形成且迁移速度较快的结缔组织细胞和上皮细胞进入骨缺损区,允许有潜在生长能力、迁移速度较慢的前体成骨细胞优先进入骨缺损区,优势生长,同时保护血凝块,减缓组织压力,实现缺损区的骨修复性再生。屏障膜在引导骨再生中起着关键作用,因此这一技术也被称为膜引导技术或膜引导再生技术。但是,现有的屏障膜对成骨细胞黏附和增殖效果还不尽如人意。
发明内容
有鉴于此,本发明的目的在于提供一种骨再生超细纤维膜及其制备方法,该纤维膜具有促进成骨细胞黏附和增殖的效果。
为了解决上述技术问题,本发明提供了一种骨再生超细纤维膜的制备方法,包括如下步骤:
S1.将贝壳粉碎研磨得到碳酸钙粉末;
S2.将所述碳酸钙粉末在氧气氛围下升温至600-800℃,高温焙烧2h,得到纯化碳酸钙粉末;
S3.将所述纯化碳酸钙粉末加入到烷基多糖苷溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置后过滤去滤液,乙醇洗涤,真空干燥,得有机碳酸钙粉末;
S4.将所述有机碳酸钙粉末加入阿仑膦酸钠溶液,充分搅拌,过滤去滤液后干燥,得到阿仑膦酸-碳酸钙插层粉末;
S5.将所述阿仑膦酸-碳酸钙插层粉末加入到酪蛋白磷酸肽、聚氧化乙烯和聚乙烯醇的混合溶液中,搅拌均匀得到核层前驱体溶液;
S6.将聚己内酯和聚乙烯基吡咯烷酮加入二氯甲烷中,得到壳层前驱体溶液;
S7.将所述核层前驱体溶液和所述壳层前驱体溶液,采用同轴静电纺丝,制备得到超细纤维膜,经烘干得到骨再生超细纤维膜。
优选的,上述制备方法的步骤S1中,所述碳酸钙粉末的粒度为200-500nm。
优选的,上述制备方法的步骤S2中,升温的速率为20-30℃/min。
优选的,上述制备方法的步骤S3中,所述烷基多糖苷溶液的溶质为APG0810、APG1214、APG0814、 APG0816、APG1216和APG2000中的一种;所述烷基多糖苷溶液的浓度为80-100g/L,所述纯化碳酸钙粉末与所述烷基多糖苷溶液的比例为1g:(80-135)mL。
优选的,上述制备方法的步骤S4中,阿仑膦酸钠溶液浓度为3-9g/L,有机碳酸钙粉末与阿仑膦酸钠溶液的比例为1g:(50-100)mL。
优选的,上述制备方法的步骤S5中,阿仑膦酸-碳酸钙插层粉末、酪蛋白磷酸肽、聚氧化乙烯、聚乙烯醇和水的比例为(1-1.5)g:(3-5)g:(4-5)g:(6-8)g:100mL。
优选的,上述制备方法的步骤S5中,所述聚氧化乙烯平均分子量为100000-600000;聚乙烯醇平均分子量为9000-10000,醇解度为80%。
优选的,上述制备方法的步骤S6中,聚己内酯、聚乙烯基吡咯烷酮和二氯甲烷的比例为 (8-12)g:(4-6)g:100mL,其中,聚己内酯平均分子量为60000-80000,聚乙烯基吡咯烷酮平均分子量为 10000-40000。
优选的,上述制备方法的步骤S7中,同轴静电纺丝条件为:纺丝电压20-25kV,壳层前驱体溶液流速0.8-1.3mL/h,核层前驱体溶液流速0.5-1mL/h,接收距离13-20cm。
本发明还提供了一种上述制备方法制备得到的骨再生超细纤维膜。
与现有技术相比,本发明具有以下有益效果:
1)本发明利用烷基多糖苷作为碳酸钙层状结构的插层剂,增大和活化碳酸钙表面,使其能够更多的吸附阿仑膦酸。阿仑膦酸、碳酸钙和酪蛋白磷酸肽在骨骼生长或修复上具有互补作用。
2)将阿仑膦酸、碳酸钙和酪蛋白磷酸肽包载在纤维核层中,壳层采用疏水的聚己内酯,能够保持核层在水中的稳定性。
附图说明
图1是实施例1所制得的骨再生超细纤维膜的扫描电镜图;
图2是实施例1-3和对比例1-5得到的纤维膜的细胞黏附曲线图;
图3是实施例1-3和对比例1-5得到的纤维膜的细胞增殖曲线图。
具体实施方式
为了进一步理解本发明,下面结合实施例对本发明优选实施方案进行描述,但是应当理解,这些描述只是为了进一步说明本发明的特征和优点,而不是对本发明权利要求的限制。
实施例1
一种骨再生超细纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以25℃/min的速度升温至700℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将2g步骤2制得的纯化碳酸钙粉末加入到200mL浓度为90g/L的APG0810溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将1.5g步骤3制得的有机碳酸钙粉末加入120mL浓度为7g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
5.将4g酪蛋白磷酸肽、4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为 80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.2g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
6.将10g平均分子量为70000的聚己内酯和5g平均分子量为30000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
7.将步骤5制得的核层前驱体溶液和步骤6制得的壳层前驱体溶液,在纺丝电压22kV,壳层前驱体溶液流速1.0mL/h,核层前驱体溶液流速0.8mL/h,接收距离16cm的条件下,采用同轴静电纺丝,制备得到超细纤维膜,经烘干得到骨再生超细纤维膜A(图1)。
实施例2
一种骨再生超细纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为200nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以20℃/min的速度升温至600℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将2g步骤2制得的纯化碳酸钙粉末加入到160mL浓度为80g/L的APG1214溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将1.5g步骤3制得的有机碳酸钙粉末加入75mL浓度为3g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
5.将3g酪蛋白磷酸肽、4g平均分子量为100000的聚氧化乙烯和6g平均分子量为9000、醇解度为80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
6.将8g平均分子量为60000的聚己内酯和4g平均分子量为10000的聚乙烯基吡咯烷酮加入100mL二氯甲烷中,得到壳层前驱体溶液;
7.将步骤5制得的核层前驱体溶液和步骤6制得的壳层前驱体溶液,在纺丝电压20kV,壳层前驱体溶液流速0.8mL/h,核层前驱体溶液流速0.5mL/h,接收距离13cm的条件下,采用同轴静电纺丝,制备得到超细纤维膜,经烘干得到骨再生超细纤维膜B。
实施例3
一种骨再生超细纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为500nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以30℃/min的速度升温至800℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将3g步骤2制得的纯化碳酸钙粉末加入到405mL浓度为100g/L的APG2000溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将2g步骤3制得的有机碳酸钙粉末加入200mL浓度为9g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
5.将5g酪蛋白磷酸肽、5g平均分子量为600000的聚氧化乙烯和8g平均分子量为10000、醇解度为80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.5g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
6.将12g平均分子量为80000的聚己内酯和6g平均分子量为40000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
7.将步骤5制得的核层前驱体溶液和步骤6制得的壳层前驱体溶液,在纺丝电压25kV,壳层前驱体溶液流速1.3mL/h,核层前驱体溶液流速1mL/h,接收距离20cm的条件下,采用同轴静电纺丝,制备得到超细纤维膜,经烘干得到骨再生超细纤维膜C。
对比例1
一种纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以25℃/min的速度升温至700℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将1.5g步骤2制得的纯化碳酸钙粉末加入120mL浓度为7g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
4.将4g酪蛋白磷酸肽、4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为 80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.2g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
5.将10g平均分子量为70000的聚己内酯和5g平均分子量为30000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
6.将步骤4制得的核层前驱体溶液和步骤5制得的壳层前驱体溶液,在纺丝电压22kV,壳层前驱体溶液流速1.0mL/h,核层前驱体溶液流速0.8mL/h,接收距离16cm的条件下,采用同轴静电纺丝,制备得到纤维膜,经烘干得到纤维膜D。
对比例2
一种纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将2g步骤1制得的碳酸钙粉末加入到200mL浓度为90g/L的APG0810溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
3.将1.5g步骤2制得的有机碳酸钙粉末加入120mL浓度为7g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
4.将4g酪蛋白磷酸肽、4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为 80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.2g步骤3制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
5.将10g平均分子量为70000的聚己内酯和5g平均分子量为30000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
6.将步骤4制得的核层前驱体溶液和步骤5制得的壳层前驱体溶液,在纺丝电压22kV,壳层前驱体溶液流速1.0mL/h,核层前驱体溶液流速0.8mL/h,接收距离16cm的条件下,采用同轴静电纺丝,制备得到纤维膜,经烘干得到纤维膜E。
对比例3
一种纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以25℃/min的速度升温至700℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将2g步骤2制得的纯化碳酸钙粉末加入到200mL浓度为90g/L的APG0810溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将1.5g步骤3制得的有机碳酸钙粉末加入120mL浓度为7g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
5.将4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为80%的聚乙烯醇加入 100mL水中,充分溶解形成混合溶液,再将1.2g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
6.将10g平均分子量为70000的聚己内酯和5g平均分子量为30000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
7.将步骤5制得的核层前驱体溶液和步骤6制得的壳层前驱体溶液,在纺丝电压22kV,壳层前驱体溶液流速1.0mL/h,核层前驱体溶液流速0.8mL/h,接收距离16cm的条件下,采用同轴静电纺丝,制备得到纤维膜,经烘干得到纤维膜F。
对比例4
一种纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以25℃/min的速度升温至700℃,高温焙烧2h,得到纯化碳酸钙粉末;
3.将2g步骤2制得的纯化碳酸钙粉末加入到200mL浓度为90g/L的APG0810溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将4g酪蛋白磷酸肽、4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为 80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.2g步骤3制得的有机碳酸钙粉末加入到混合溶液中,搅拌均匀得到核层前驱体溶液;
5.将10g平均分子量为70000的聚己内酯和5g平均分子量为30000的聚乙烯基吡咯烷酮加入100mL 二氯甲烷中,得到壳层前驱体溶液;
6.将步骤4制得的核层前驱体溶液和步骤5制得的壳层前驱体溶液,在纺丝电压22kV,壳层前驱体溶液流速1.0mL/h,核层前驱体溶液流速0.8mL/h,接收距离16cm的条件下,采用同轴静电纺丝,制备得到纤维膜,经烘干得到纤维膜G。
对比例5
一种纤维膜及其制备方法,包括如下步骤:
1.将贝壳粉碎研磨得到粒度为300nm的碳酸钙粉末;
2.将步骤1制备的碳酸钙粉末置于坩埚内,在氧气氛围下以25℃/min的速度升温至700℃,高温焙烧 2h,得到纯化碳酸钙粉末;
3.将2g步骤2制得的纯化碳酸钙粉末加入到200mL浓度为90g/L的APG0810溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置沉淀,过滤用乙醇洗涤后,真空干燥得有机碳酸钙粉末;
4.将1.5g步骤3制得的有机碳酸钙粉末加入120mL浓度为7g/L的阿仑膦酸钠溶液,充分搅拌,过滤后沉淀经干燥,得到阿仑膦酸-碳酸钙插层粉末;
5.将4g酪蛋白磷酸肽、4.5g平均分子量为400000的聚氧化乙烯和7g平均分子量为9500、醇解度为 80%的聚乙烯醇加入100mL水中,充分溶解形成混合溶液,再将1.2g步骤4制得的阿仑膦酸-碳酸钙插层粉末加入到混合溶液中,搅拌均匀得到前驱体溶液;
6.将步骤5制得的前驱体溶液,在纺丝电压22kV,前驱体溶液流速1.0mL/h,接收距离16cm的条件下,采用静电纺丝,制备得到纤维膜,经烘干得到纤维膜H。
细胞黏附和增殖实验
细胞:小鼠成骨细胞(CP-M091)
培养基:小鼠成骨细胞完全培养基
培养条件:5%CO2,37℃
方法:用打孔机将实施例1-3和对比例1-5的纤维膜裁剪成直径6mm的圆片,使用前用紫外线照射 30min,备用。实验前1d将材料放入96孔培养板中,用培养基预湿,备用。
将圆片铺于孔底,取常规传代培养的小鼠成骨细胞经消化后,调整细胞密度为5×103/mL,在孔中加入100μL细胞悬液,分别于1h,4h,7h取出材料,用PBS溶液漂洗2遍,去除死细胞,移入新96孔板,每孔一块,加入新鲜培养基100μl后避光加入CCK-810μL,吹打均匀,置于37℃恒温培养箱孵育2h后,吸取100μL培养液加入96孔板,在490nm处测量各孔吸光度。每个样品五次重复,计算平均值。以时间为横坐标,吸光度为纵坐标绘制细胞黏附曲线图,如图2所示。
取常规传代培养的小鼠成骨细胞经消化后,调整细胞密度为5×103/mL,取100μL细胞悬液接种于各组96孔板内已经预湿的膜材料上,分别于1d,3d,5d,取出材料,用PBS溶液漂洗2遍,去除死细胞,移入新96孔板,每孔一块,加入新鲜培养基100μL后避光加入CCK-810μL,吹打均匀,置于37℃恒温培养箱孵育2h后,吸取100μL培养液加入96孔板,在490nm处测量各孔吸光度。每个样品五次重复,计算平均值。以时间为横坐标,吸光度为纵坐标绘制细胞增殖曲线图,如图3所示。
由图2和图3可知,经本发明实施例制备的纤维膜处理的小鼠成骨细胞其黏附效果和增殖率明显优于各对比例纤维膜。纤维膜中的阿仑膦酸、酪蛋白磷酸肽/钙复合物的协同作用促使成骨细胞在纤维膜表面的黏附和增殖。对比例1-4中缺乏其协同作用,所以效果不如实施例。对比例5由于没有采用同轴电纺,单一的聚氧化乙烯和聚乙烯醇在细胞培养环境下会迅速的溶胀降解,这对于屏障结缔组织细胞和上皮细胞是不利的。只有实施例才能达到既屏障结缔组织细胞和上皮细胞同时促进成骨细胞黏附和增殖。
本发明提供了一种骨再生超细纤维膜及其制备方法的思路及方法,具体实现该技术方案的方法和途径很多,以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。本实施例中未明确的各组成部分均可用现有技术加以实现。
Claims (10)
1.一种骨再生超细纤维膜的制备方法,其特征在于,包括如下步骤:
S1.将贝壳粉碎研磨得到碳酸钙粉末;
S2.将所述碳酸钙粉末在氧气氛围下升温至600-800℃,高温焙烧2h,得到纯化碳酸钙粉末;
S3.将所述纯化碳酸钙粉末加入到烷基多糖苷溶液中,充分搅拌得均匀的糊状物,用盐酸溶液调pH值为7.0,静置后过滤去滤液,乙醇洗涤,真空干燥,得有机碳酸钙粉末;
S4.将所述有机碳酸钙粉末加入阿仑膦酸钠溶液,充分搅拌,过滤去滤液后干燥,得到阿仑膦酸-碳酸钙插层粉末;
S5.将酪蛋白磷酸肽、聚氧化乙烯和聚乙烯醇加入水中得到酪蛋白磷酸肽、聚氧化乙烯和聚乙烯醇的混合溶液;将所述阿仑膦酸-碳酸钙插层粉末加入到所述酪蛋白磷酸肽、聚氧化乙烯和聚乙烯醇的混合溶液中,搅拌均匀得到核层前驱体溶液;
S6.将聚己内酯和聚乙烯基吡咯烷酮加入二氯甲烷中,得到壳层前驱体溶液;
S7.将所述核层前驱体溶液和所述壳层前驱体溶液,采用同轴静电纺丝,制备得到超细纤维膜,经烘干得到骨再生超细纤维膜。
2.根据权利要求1所述的制备方法,其特征在于,步骤S1中,所述碳酸钙粉末的粒度为200-500nm。
3.根据权利要求1所述的制备方法,其特征在于,所述步骤S2中,升温的速率为20-30℃/min。
4.根据权利要求1所述的制备方法,其特征在于,步骤S3中,所述烷基多糖苷溶液的溶质为APG0810、APG1214、APG0814、APG0816、APG1216和APG2000中的一种;所述烷基多糖苷溶液的浓度为80-100g/L,所述纯化碳酸钙粉末与所述烷基多糖苷溶液的比例为1g:(80-135)mL。
5.根据权利要求1所述的制备方法,其特征在于,所述步骤S4中,阿仑膦酸钠溶液浓度为3-9g/L,有机碳酸钙粉末与阿仑膦酸钠溶液的比例为1g:(50-100)mL。
6.根据权利要求1所述的制备方法,其特征在于,所述步骤S5中,阿仑膦酸-碳酸钙插层粉末、酪蛋白磷酸肽、聚氧化乙烯、聚乙烯醇和水的比例为(1-1.5)g:(3-5)g:(4-5)g:(6-8)g:100mL。
7.根据权利要求1所述的制备方法,其特征在于,步骤S5中,所述聚氧化乙烯平均分子量为100000-600000;聚乙烯醇平均分子量为9000-10000,醇解度为80%。
8.根据权利要求1所述的制备方法,其特征在于,所述步骤S6中,聚己内酯、聚乙烯基吡咯烷酮和二氯甲烷的比例为(8-12)g:(4-6)g:100mL,其中,聚己内酯平均分子量为60000-80000,聚乙烯基吡咯烷酮平均分子量为10000-40000。
9.根据权利要求1所述的制备方法,其特征在于,所述步骤S7中,同轴静电纺丝条件为:纺丝电压20-25kV,壳层前驱体溶液流速0.8-1.3mL/h,核层前驱体溶液流速0.5-1mL/h,接收距离13-20cm。
10.根据权利要求1~9任一项所述制备方法制备得到的骨再生超细纤维膜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110387580.4A CN113318280B (zh) | 2021-04-09 | 2021-04-09 | 一种骨再生超细纤维膜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110387580.4A CN113318280B (zh) | 2021-04-09 | 2021-04-09 | 一种骨再生超细纤维膜及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113318280A CN113318280A (zh) | 2021-08-31 |
CN113318280B true CN113318280B (zh) | 2022-06-21 |
Family
ID=77414675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110387580.4A Active CN113318280B (zh) | 2021-04-09 | 2021-04-09 | 一种骨再生超细纤维膜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113318280B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139833A (zh) * | 2023-02-22 | 2023-05-23 | 南通大学 | 一种含铅废水处理剂及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR517701A0 (en) * | 2001-05-21 | 2001-06-14 | University Of Melbourne, The | Dental restorative materials |
CN1727530A (zh) * | 2005-07-26 | 2006-02-01 | 天津大学 | 芯/壳结构的超细纤维膜材料及其制备方法 |
JP5179124B2 (ja) * | 2007-09-06 | 2013-04-10 | 矢橋工業株式会社 | 骨再生誘導膜、およびその製造方法 |
CN102817105A (zh) * | 2012-08-24 | 2012-12-12 | 上海交通大学 | 核壳结构合成高分子-天然高分子复合纤维的制备方法 |
US20160355951A1 (en) * | 2013-03-15 | 2016-12-08 | Arsenal Medical, Inc. | Core-sheath fibers and methods of making and using same |
CN103585678B (zh) * | 2013-11-14 | 2015-05-13 | 中山大学 | 一种酪蛋白-碳酸钙微球改性聚乳酸膜材料及其制备方法和应用 |
KR101685295B1 (ko) * | 2015-07-02 | 2016-12-12 | 단국대학교 천안캠퍼스 산학협력단 | 다중 약물 탑재 스캐폴드 및 이의 용도 |
CN107224619A (zh) * | 2017-06-19 | 2017-10-03 | 兰州大学 | 同轴静电纺丝制备ica‑sf/plcl纳米纤维膜的方法及作为gbr膜的应用 |
CN107661539A (zh) * | 2017-10-31 | 2018-02-06 | 无锡中科光远生物材料有限公司 | 一种壳核结构的药物缓释涂层材料 |
CN108560144A (zh) * | 2018-02-05 | 2018-09-21 | 中山大学 | 一种提高plga电纺纤维膜稳定性及生物活性的方法 |
WO2020056467A1 (en) * | 2018-09-23 | 2020-03-26 | University Of Wollongong | An implantable device and a method for implanting said device in a subject |
CN110180032A (zh) * | 2019-06-12 | 2019-08-30 | 东华大学 | 一种载药控释的同轴静电纺丝纳米纤维支架及其制备方法和应用 |
CN111588912B (zh) * | 2020-06-10 | 2021-06-29 | 四川大学 | 一种用于骨组织再生的多功能纤维膜及其制备方法 |
-
2021
- 2021-04-09 CN CN202110387580.4A patent/CN113318280B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113318280A (zh) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103495210B (zh) | 壳聚糖-羟基磷灰石原位负载淫羊藿苷复合微球 | |
CN106729928A (zh) | 一种聚乙烯醇/海藻酸钠/羟基磷灰石复合纤维膜及其制备方法、应用 | |
CN113318280B (zh) | 一种骨再生超细纤维膜及其制备方法 | |
CN113398327B (zh) | 一种高生物活性MXene/生物玻璃微球复合材料的制备方法 | |
CN112107731A (zh) | 一种可注射双层载药骨软骨修复水凝胶支架及其制备方法 | |
CN101264341A (zh) | 三维多孔组织工程支架材料、其制备及应用 | |
CN113082293A (zh) | 一种仿生矿化胶原成骨支架及其制备方法 | |
CN106730033A (zh) | 一种兼具抗菌和促生长的双效载药纳米颗粒微球及其制备方法和应用 | |
CN109260150A (zh) | 用于修复牙周炎骨缺损的芯-壳同轴纳米纤维及其制备方法与用途 | |
DE60100500T2 (de) | Suspension enthaltend ein epi-hne protein, verfahren zu ihrer herstellung, daraus hergestelltes trockenpulveraerosol, arzneimittelzusammensetzungen enthaltend diese suspension oder dieses aerosol und ihre verwendungen | |
CN107823704A (zh) | 一种牙周组织再生修复膜及其制备方法 | |
CN113398334B (zh) | 碳量子点水凝胶复合支架材料及制备方法和应用 | |
CN102491299B (zh) | 纳米羟基磷灰石的制备方法 | |
CN110468503B (zh) | 一种复合纳米纤维膜及其制备方法和应用 | |
CN115998962A (zh) | 一种组织粘附性复合水凝胶的合成方法及其绿色序列治疗种植体周围炎的应用 | |
KR102336328B1 (ko) | 고체 원물이 포함된 바이오셀룰로오스, 이를 제조하기 위한 배지 조성물 및 이의 제조방법 | |
CN114272443B (zh) | 硅酸锌纳米颗粒复合纤维支架的制备方法和应用 | |
CN113679887B (zh) | 一种生物活性复合材料在牙周骨缺损修复和/或牙周骨再生方面的应用 | |
CN106890364A (zh) | 一种工程化牙周组织的制备方法 | |
CN113827768B (zh) | 一种载溶血磷脂酸纳米颗粒的仿生支架的制备方法 | |
DE10126137C1 (de) | Verfahren zur Herstellung von Zellen, Geweben und Organen | |
Cheng et al. | Biphasic calcium phosphate/chitosan/polyacrylonitrile/polylactic acid-glycolic acid (PLGA) nanocomposite stent for repair and osteogenesis of oral alveolar bone defect | |
CN112870442A (zh) | 一种双面引导骨修复膜及其制备方法和应用 | |
CN111514372B (zh) | CaCO3/MgO纳米复合物及其在骨修复中的应用 | |
CN108525004A (zh) | α-半水石膏/羟基磷灰石复合微球及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240507 Address after: 230000 B-1015, wo Yuan Garden, 81 Ganquan Road, Shushan District, Hefei, Anhui. Patentee after: HEFEI MINGLONG ELECTRONIC TECHNOLOGY Co.,Ltd. Country or region after: China Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University Country or region before: China |